Clinical Features Associated With Nascent Left Ventricular Diastolic Dysfunction in a Population Aged 40 to 55 Years - 28/05/18
, Rebecca T. Levinson, PhD a, b, Evan L. Brittain, MD a, b, Deepak K. Gupta, MD a, b, Eric Farber-Eger, BS a, b, Christian M. Shaffer, BS a, Josh C. Denny, MD a, b, Dan M. Roden, MD a, c, d, Quinn S. Wells, MD a, b, dAbstract |
Diastolic dysfunction (DD), an abnormality in cardiac left ventricular (LV) chamber compliance, is associated with increased morbidity and mortality. Although DD has been extensively studied in older populations, co-morbidity patterns are less well characterized in middle-aged subjects. We screened 156,434 subjects with transthoracic echocardiogram reports available through Vanderbilt's electronic heath record and identified 6,612 subjects 40 to 55 years old with an LV ejection fraction ≥50% and diastolic function staging. We tested 452 incident and prevalent clinical diagnoses for associations with early-stage DD (n = 1,676) versus normal function. There were 44 co-morbid diagnoses associated with grade 1 DD including hypertension (odds ratio [OR] = 2.02, 95% confidence interval [CI] 1.78 to 2.28, p <5.3 × 10−29), type 2 diabetes (OR 1.96, 95% CI 1.68 to 2.29, p = 2.1 × 10−17), tachycardia (OR 1.38, 95% CI 0.53 to 2.19, p = 2.9 × 10−6), obesity (OR 1.76, 95% CI 1.51 to 2.06, p = 1.7 × 10−12), and clinical end points, including end-stage renal disease (OR 3.29, 95% CI 2.19 to 4.96, p = 1.2 × 10−8) and stroke (OR 1.5, 95% CI 1.12 to 2.02, p = 6.9 × 10−3). Among the 60 incident diagnoses associated with DD, heart failure with preserved ejection fraction (OR 4.63, 95% CI 3.39 to 6.32, p = 6.3 × 10−22) had the most significant association. Among subjects with normal diastolic function and blood pressure at baseline, a blood pressure measurement in the hypertensive range at the time of the second echocardiogram was associated with progression to stage 1 DD (p = 0.04). In conclusion, DD was common among subjects 40 to 55 years old and was associated with a heavy burden of co-morbid disease.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| This work was supported by a career development award from the Vanderbilt Faculty Research Scholars Fund (JDM), the American Heart Association (AHA) (Dallas, Texas) 16FTF30130005 (JDM), AHA 13FTF16810038 (QSW), AHA 17IBDG33780015 (QSW), National Institutes of Health ((Bethesda, Maryland)/National Heart, Lung, and Blood Institute (QSW), NIH/NHLBI K23HL128928-02 (DKG), and AHA 13FTF16070002 (ELB). The Vanderbilt University Medical Center's Synthetic Derivative is supported by numerous sources: institutional funding, private agencies, and federal grants, including the NIH-funded Shared Instrumentation Grant S10RR025141 and Clinical and Translational Science Award grants UL1TR002243, UL1TR000445, and UL1RR024975. |
|
| See page 1557 for disclosure information. |
Vol 121 - N° 12
P. 1552-1557 - giugno 2018 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
